How Gene Therapy and CAR T-Cell Therapy Are Changing Lives

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-10-02T23:55:36.655Z • Permanent link

Gene therapy has been gaining momentum for over two decades, but it wasn't until the emergence of CAR T-cell therapy that the field truly began to accelerate. This breakthrough treatment, developed by scientists at the National Cancer Institute, involves genetically modifying a patient's own T-cells to recognize and attack cancer cells. The first CAR T-cell therapy, tisagenlecleucel, was approved by the FDA in 2017 for the treatment of certain types of blood cancers, such as leukemia and lymphoma.

The success of CAR T-cell therapy has been nothing short of remarkable, with studies showing that it can achieve complete remission in patients who would otherwise have been considered incurable. One notable example is the case of Tessa Gansler, a 9-year-old girl who was diagnosed with acute lymphoblastic leukemia in 2016. After undergoing CAR T-cell therapy, Tessa's cancer went into complete remission, and she has since become an advocate for gene therapy and cancer research.

The development of CAR T-cell therapy has also been driven by the efforts of companies such as Novartis and Kite Pharma, which have invested heavily in research and development. In 2019, Novartis acquired Kite Pharma for $11.9 billion, giving the company a significant stake in the emerging CAR T-cell market. The acquisition has allowed Novartis to expand its portfolio of gene therapies and bring new treatments to patients with blood cancers.

The impact of CAR T-cell therapy on the Biotech & Medical domain cannot be overstated. The treatment has already shown significant promise in treating a range of blood cancers, and its success has paved the way for further research into gene therapy and immunotherapy. The biotech industry has taken notice, with many companies investing heavily in gene therapy and CAR T-cell research. For example, the biotech company, Juno Therapeutics, has developed a range of CAR T-cell therapies for the treatment of blood cancers, and its partnership with Bristol-Myers Squibb has given the company access to significant resources and expertise.

The real-world impact of CAR T-cell therapy is also being felt in the medical community. Doctors and researchers are increasingly turning to gene therapy as a treatment option for patients with blood cancers, and the treatment has already shown significant promise in clinical trials. The success of CAR T-cell therapy has also raised hopes for the treatment of other diseases, such as multiple sclerosis and leukemia. As the technology continues to evolve, it is likely that we will see even more innovative treatments emerge.

The emergence of CAR T-cell therapy is part of a larger trend in the Biotech & Medical domain, which has seen significant investment in gene therapy and immunotherapy research. The success of CAR T-cell therapy has also been driven by the efforts of researchers at institutions such as the National Cancer Institute and the University of Pennsylvania, who have made significant contributions to the field of gene therapy. The development of CAR T-cell therapy has also been influenced by the work of companies such as Celgene, which has developed a range of gene therapies for the treatment of blood cancers.